ID   DAPK2_HUMAN             Reviewed;         370 AA.
AC   Q9UIK4; E9JGM7; O75892; Q24JS1;
DT   28-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   15-MAR-2017, entry version 161.
DE   RecName: Full=Death-associated protein kinase 2;
DE            Short=DAP kinase 2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:26047703};
DE   AltName: Full=DAP-kinase-related protein 1;
DE            Short=DRP-1;
GN   Name=DAPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:BAA88063.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, ENZYME REGULATION, TISSUE
RP   SPECIFICITY, MUTAGENESIS OF LYS-52, AND CATALYTIC ACTIVITY.
RC   TISSUE=Skeletal muscle {ECO:0000269|PubMed:10376525};
RX   PubMed=10376525; DOI=10.1038/sj.onc.1202701;
RA   Kawai T., Nomura F., Hoshino K., Copeland N.G., Gilbert D.J.,
RA   Jenkins N.A., Akira S.;
RT   "Death-associated protein kinase 2 is a new calcium/calmodulin-
RT   dependent protein kinase that signals apoptosis through its catalytic
RT   activity.";
RL   Oncogene 18:3471-3480(1999).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION,
RP   HOMODIMERIZATION, AND MUTAGENESIS OF LYS-52.
RC   TISSUE=Kidney {ECO:0000312|EMBL:AAC35001.1};
RX   PubMed=10629061; DOI=10.1128/MCB.20.3.1044-1054.2000;
RA   Inbal B., Shani G., Cohen O., Kissil J.L., Kimchi A.;
RT   "Death-associated protein kinase-related protein 1, a novel
RT   serine/threonine kinase involved in apoptosis.";
RL   Mol. Cell. Biol. 20:1044-1054(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), TISSUE
RP   SPECIFICITY, AND INTERACTION WITH ATF4 (ISOFORM 2).
RX   PubMed=21408167; DOI=10.1371/journal.pone.0017344;
RA   Shoval Y., Berissi H., Kimchi A., Pietrokovski S.;
RT   "New modularity of DAP-kinases: alternative splicing of the DRP-1 gene
RT   produces a ZIPk-like isoform.";
RL   PLoS ONE 6:E17344-E17344(2011).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, HOMODIMERIZATION, MUTAGENESIS OF LYS-52; SER-299; SER-318;
RP   SER-320; SER-323 AND THR-329, AND PHOSPHORYLATION AT SER-318.
RX   PubMed=11230133; DOI=10.1093/emboj/20.5.1099;
RA   Shani G., Henis-Korenblit S., Jona G., Gileadi O., Eisenstein M.,
RA   Ziv T., Admon A., Kimchi A.;
RT   "Autophosphorylation restrains the apoptotic activity of DRP-1 kinase
RT   by controlling dimerization and calmodulin binding.";
RL   EMBO J. 20:1099-1113(2001).
RN   [7]
RP   REVIEW.
RX   PubMed=12445458; DOI=10.1016/S1570-9639(02)00443-0;
RA   Shohat G., Shani G., Eisenstein M., Kimchi A.;
RT   "The DAP-kinase family of proteins: study of a novel group of calcium-
RT   regulated death-promoting kinases.";
RL   Biochim. Biophys. Acta 1600:45-50(2002).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11980920; DOI=10.1083/jcb.200109094;
RA   Inbal B., Bialik S., Sabanay I., Shani G., Kimchi A.;
RT   "DAP kinase and DRP-1 mediate membrane blebbing and the formation of
RT   autophagic vesicles during programmed cell death.";
RL   J. Cell Biol. 157:455-468(2002).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=16756490; DOI=10.1146/annurev.biochem.75.103004.142615;
RA   Bialik S., Kimchi A.;
RT   "The death-associated protein kinases: structure, function, and
RT   beyond.";
RL   Annu. Rev. Biochem. 75:189-210(2006).
RN   [10]
RP   FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17347302; DOI=10.1189/jlb.0606400;
RA   Rizzi M., Tschan M.P., Britschgi C., Britschgi A., Huegli B.,
RA   Grob T.J., Leupin N., Mueller B.U., Simon H.U., Ziemiecki A.,
RA   Torbett B.E., Fey M.F., Tobler A.;
RT   "The death-associated protein kinase 2 is up-regulated during normal
RT   myeloid differentiation and enhances neutrophil maturation in myeloid
RT   leukemic cells.";
RL   J. Leukoc. Biol. 81:1599-1608(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-349, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   FUNCTION.
RX   PubMed=18957423; DOI=10.1074/jbc.M805612200;
RA   Li H., Ray G., Yoo B.H., Erdogan M., Rosen K.V.;
RT   "Down-regulation of death-associated protein kinase-2 is required for
RT   beta-catenin-induced anoikis resistance of malignant epithelial
RT   cells.";
RL   J. Biol. Chem. 284:2012-2022(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-299 AND SER-349, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=24163421; DOI=10.1189/jlb.0813462;
RA   Geering B., Stoeckle C., Rozman S., Oberson K., Benarafa C.,
RA   Simon H.U.;
RT   "DAPK2 positively regulates motility of neutrophils and eosinophils in
RT   response to intermediary chemoattractants.";
RL   J. Leukoc. Biol. 95:293-303(2014).
RN   [15]
RP   INTERACTION WITH 14-3-3 PROTEINS, MUTAGENESIS OF SER-367; SER-368;
RP   THR-369 AND SER-370, PHOSPHORYLATION AT THR-369, FUNCTION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=26047703; DOI=10.1016/j.bbrc.2015.05.105;
RA   Yuasa K., Ota R., Matsuda S., Isshiki K., Inoue M., Tsuji A.;
RT   "Suppression of death-associated protein kinase 2 by interaction with
RT   14-3-3 proteins.";
RL   Biochem. Biophys. Res. Commun. 464:70-75(2015).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-60 AND TRP-271.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium/calmodulin-dependent serine/threonine kinase
CC       involved in multiple cellular signaling pathways that trigger cell
CC       survival, apoptosis, and autophagy. Regulates both type I
CC       apoptotic and type II autophagic cell death signals, depending on
CC       the cellular setting. The former is caspase-dependent, while the
CC       latter is caspase-independent and is characterized by the
CC       accumulation of autophagic vesicles. Acts as a mediator of anoikis
CC       and a suppressor of beta-catenin-dependent anchorage-independent
CC       growth of malignant epithelial cells. May play a role in
CC       granulocytic maturation (PubMed:17347302). Regulates granulocytic
CC       motility by controlling cell spreading and polarization
CC       (PubMed:24163421). {ECO:0000269|PubMed:17347302,
CC       ECO:0000269|PubMed:24163421, ECO:0000269|PubMed:26047703}.
CC   -!- FUNCTION: Isoform 2 is not regulated by calmodulin. It can
CC       phosphorylate MYL9. It can induce membrane blebbing and autophagic
CC       cell death.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:26047703}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10376525,
CC         ECO:0000269|PubMed:10629061, ECO:0000269|PubMed:11230133};
CC   -!- ENZYME REGULATION: Activated by Ca(2+)/calmodulin. Regulated by a
CC       double locking mechanism, involving autophosphorylation at Ser-
CC       318, calmodulin binding, and dimerization. In the inactive state,
CC       Ser-318 is phosphorylated, and the kinase is dimeric. Activation
CC       involves: dephosphorylation at Ser-318, release-of-autoinhibition
CC       mechanism where calmodulin binding induces a conformational change
CC       that relieves the steric block of the active site by the
CC       autoinhibitory domain, and generation of the monomeric active form
CC       of the kinase. {ECO:0000269|PubMed:10376525}.
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer
CC       (By similarity). Isoform 2 but not isoform 1 can interact with
CC       ATF4. Interacts with 14-3-3 proteins YWHAB, YWHAE, YWHAG, YWHAH,
CC       YWHAQ, YWHAZ and SFN; the interaction requires DAPK2
CC       phosphorylation at Thr-369 and suppresses DAPK2 kinase activity
CC       and DAPK2-induced apoptosis (PubMed:26047703). {ECO:0000250,
CC       ECO:0000269|PubMed:26047703}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-77154, EBI-77154;
CC       P18848:ATF4; NbExp=2; IntAct=EBI-9693115, EBI-492498;
CC       Q8IZU0:FAM9B; NbExp=3; IntAct=EBI-77154, EBI-10175124;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasmic vesicle,
CC       autophagosome lumen.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q9UIK4-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta;
CC         IsoId=Q9UIK4-2; Sequence=VSP_042057;
CC         Note=Contains a leucine zipper at positions 434-451.;
CC   -!- TISSUE SPECIFICITY: Expressed in neutrophils and eosinophils
CC       (PubMed:24163421). Isoform 2 is expressed in embryonic stem cells
CC       (at protein level). Isoform 1 is ubiquitously expressed in all
CC       tissue types examined with high levels in heart, lung and skeletal
CC       muscle. {ECO:0000269|PubMed:10376525, ECO:0000269|PubMed:17347302,
CC       ECO:0000269|PubMed:21408167, ECO:0000269|PubMed:24163421}.
CC   -!- INDUCTION: Up-regulated during granulocytic maturation
CC       (PubMed:17347302, PubMed:24163421). {ECO:0000269|PubMed:17347302,
CC       ECO:0000269|PubMed:24163421}.
CC   -!- DOMAIN: The autoinhibitory domain sterically blocks the substrate
CC       peptide-binding site by making both hydrophobic and electrostatic
CC       contacts with the kinase core. {ECO:0000250}.
CC   -!- PTM: Autophosphorylation at Ser-318 inhibits its catalytic
CC       activity. Dephosphorylated at Ser-318 in response to activated Fas
CC       and TNF-alpha receptors. {ECO:0000269|PubMed:11230133}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. DAP kinase subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB018001; BAA88063.1; -; mRNA.
DR   EMBL; AF052941; AAC35001.1; -; mRNA.
DR   EMBL; GU056176; ADD83109.1; -; mRNA.
DR   EMBL; AC015914; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC021541; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC114506; AAI14507.1; -; mRNA.
DR   CCDS; CCDS10188.1; -. [Q9UIK4-1]
DR   RefSeq; NP_055141.2; NM_014326.3. [Q9UIK4-1]
DR   RefSeq; XP_011519718.1; XM_011521416.2. [Q9UIK4-2]
DR   UniGene; Hs.237886; -.
DR   PDB; 1WMK; X-ray; 3.60 A; A/B/C/D/E/F/G/H=11-330.
DR   PDB; 1WRZ; X-ray; 2.00 A; B=312-330.
DR   PDB; 1Z9X; X-ray; 3.93 A; A/B/C=11-330.
DR   PDB; 1ZUZ; X-ray; 1.91 A; B=312-330.
DR   PDB; 1ZWS; X-ray; 2.90 A; A/B/C/D/E/F/G/H=11-297.
DR   PDB; 2A27; X-ray; 3.00 A; A/B/C/D/E/F/G/H=11-330.
DR   PDB; 2A2A; X-ray; 1.47 A; A/B/C/D=11-330.
DR   PDB; 2CKE; X-ray; 2.80 A; A/B/C/D=11-330.
DR   PDBsum; 1WMK; -.
DR   PDBsum; 1WRZ; -.
DR   PDBsum; 1Z9X; -.
DR   PDBsum; 1ZUZ; -.
DR   PDBsum; 1ZWS; -.
DR   PDBsum; 2A27; -.
DR   PDBsum; 2A2A; -.
DR   PDBsum; 2CKE; -.
DR   ProteinModelPortal; Q9UIK4; -.
DR   SMR; Q9UIK4; -.
DR   BioGrid; 117137; 8.
DR   IntAct; Q9UIK4; 8.
DR   STRING; 9606.ENSP00000261891; -.
DR   BindingDB; Q9UIK4; -.
DR   ChEMBL; CHEMBL3123; -.
DR   GuidetoPHARMACOLOGY; 2003; -.
DR   iPTMnet; Q9UIK4; -.
DR   PhosphoSitePlus; Q9UIK4; -.
DR   BioMuta; DAPK2; -.
DR   DMDM; 38605084; -.
DR   EPD; Q9UIK4; -.
DR   PaxDb; Q9UIK4; -.
DR   PeptideAtlas; Q9UIK4; -.
DR   PRIDE; Q9UIK4; -.
DR   DNASU; 23604; -.
DR   Ensembl; ENST00000261891; ENSP00000261891; ENSG00000035664. [Q9UIK4-1]
DR   Ensembl; ENST00000457488; ENSP00000408277; ENSG00000035664. [Q9UIK4-1]
DR   Ensembl; ENST00000558069; ENSP00000453235; ENSG00000035664. [Q9UIK4-2]
DR   Ensembl; ENST00000612884; ENSP00000484390; ENSG00000035664. [Q9UIK4-2]
DR   GeneID; 23604; -.
DR   KEGG; hsa:23604; -.
DR   UCSC; uc002amr.4; human. [Q9UIK4-1]
DR   CTD; 23604; -.
DR   DisGeNET; 23604; -.
DR   GeneCards; DAPK2; -.
DR   HGNC; HGNC:2675; DAPK2.
DR   HPA; HPA071581; -.
DR   MIM; 616567; gene.
DR   neXtProt; NX_Q9UIK4; -.
DR   OpenTargets; ENSG00000035664; -.
DR   PharmGKB; PA27143; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; ENOG410XRMJ; LUCA.
DR   GeneTree; ENSGT00760000118877; -.
DR   HOGENOM; HOG000233016; -.
DR   HOVERGEN; HBG100551; -.
DR   InParanoid; Q9UIK4; -.
DR   KO; K08803; -.
DR   OMA; NLRNCES; -.
DR   PhylomeDB; Q9UIK4; -.
DR   TreeFam; TF314166; -.
DR   Reactome; R-HSA-418889; Ligand-independent caspase activation via DCC.
DR   SignaLink; Q9UIK4; -.
DR   SIGNOR; Q9UIK4; -.
DR   ChiTaRS; DAPK2; human.
DR   EvolutionaryTrace; Q9UIK4; -.
DR   GeneWiki; DAPK2; -.
DR   GenomeRNAi; 23604; -.
DR   PRO; PR:Q9UIK4; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000035664; -.
DR   CleanEx; HS_DAPK2; -.
DR   ExpressionAtlas; Q9UIK4; baseline and differential.
DR   Genevisible; Q9UIK4; HS.
DR   GO; GO:0034423; C:autophagosome lumen; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0043276; P:anoikis; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:1990266; P:neutrophil migration; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:2000424; P:positive regulation of eosinophil chemotaxis; IMP:UniProtKB.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:2001242; P:regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   InterPro; IPR020636; Ca/CaM-dep_Ca-dep_prot_Kinase.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24347; PTHR24347; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Calmodulin-binding; Complete proteome; Cytoplasm; Cytoplasmic vesicle;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    370       Death-associated protein kinase 2.
FT                                /FTId=PRO_0000085912.
FT   DOMAIN       23    285       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      29     37       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      277    344       Calmodulin-binding.
FT   REGION      292    301       Autoinhibitory domain. {ECO:0000250}.
FT   ACT_SITE    149    149       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      52     52       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:10376525,
FT                                ECO:0000269|PubMed:10629061}.
FT   MOD_RES     299    299       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     318    318       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11230133}.
FT   MOD_RES     349    349       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     369    369       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:26047703}.
FT   VAR_SEQ     287    370       PVDNQQAMVRRESVVNLENFRKQYVRRRWKLSFSIVSLCNH
FT                                LTRSLMKKVHLRPDEDLRNCESDTEEDIARRKALHPRRRSS
FT                                TS -> SKGEGRAPEQRKTEPTQLKTKHLREYTLKCHSSMP
FT                                PNNSYVNFERFACVVEDVARVDLGCRALVEAHDTIQDDVEA
FT                                LVSIFNEKEAWYREENESARHDLSQLRYEFRKVESLKKLLR
FT                                EDIQATGCSLGSMARKLDHLQAQFEILRQELSADLQWIQEL
FT                                VGSFQLESGSSEGLGSTFYQDTSESLSELLSRSCTEEFLAG
FT                                WKL (in isoform 2).
FT                                {ECO:0000303|PubMed:21408167}.
FT                                /FTId=VSP_042057.
FT   VARIANT      60     60       R -> W (in dbSNP:rs56047843).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040436.
FT   VARIANT     271    271       R -> W (in dbSNP:rs34270163).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040437.
FT   MUTAGEN      52     52       K->A: Loss of activity, apoptotic
FT                                function and of autophosphorylation.
FT                                {ECO:0000269|PubMed:10376525,
FT                                ECO:0000269|PubMed:10629061,
FT                                ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     299    330       Missing: Loss of ca(2+)-calmodulin
FT                                binding, increase in activity, loss of
FT                                autophosphorylation.
FT   MUTAGEN     299    299       S->A: No effect on Ca(2+)-calmodulin
FT                                independent phosphorylation or apoptotic
FT                                activity. {ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     318    318       S->A: Loss of Ca(2+)-calmodulin
FT                                independent phosphorylation, increase in
FT                                apoptotic activity.
FT                                {ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     318    318       S->D: Abolishes apoptotic activity.
FT                                {ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     320    320       S->A: No effect on Ca(2+)-calmodulin
FT                                independent phosphorylation or apoptotic
FT                                activity. {ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     323    323       S->A: No effect on Ca(2+)-calmodulin
FT                                independent phosphorylation or apoptotic
FT                                activity. {ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     329    329       T->A: No effect on Ca(2+)-calmodulin
FT                                independent phosphorylation or apoptotic
FT                                activity. {ECO:0000269|PubMed:11230133}.
FT   MUTAGEN     367    367       S->A: No effect on interaction with
FT                                YWHAE. {ECO:0000269|PubMed:26047703}.
FT   MUTAGEN     368    368       S->A: No effect on interaction with
FT                                YWHAE. {ECO:0000269|PubMed:26047703}.
FT   MUTAGEN     369    369       T->A: Interaction with YWHAE is reduced.
FT                                {ECO:0000269|PubMed:26047703}.
FT   MUTAGEN     370    370       S->A: Interaction with YWHAE is
FT                                increased. {ECO:0000269|PubMed:26047703}.
FT   CONFLICT    241    241       A -> S (in Ref. 2; AAC35001).
FT                                {ECO:0000305}.
FT   CONFLICT    253    253       Q -> H (in Ref. 2; AAC35001).
FT                                {ECO:0000305}.
FT   HELIX        19     22       {ECO:0000244|PDB:2A2A}.
FT   STRAND       23     31       {ECO:0000244|PDB:2A2A}.
FT   STRAND       33     42       {ECO:0000244|PDB:2A2A}.
FT   TURN         43     45       {ECO:0000244|PDB:2A2A}.
FT   STRAND       48     56       {ECO:0000244|PDB:2A2A}.
FT   STRAND       58     61       {ECO:0000244|PDB:2A2A}.
FT   STRAND       63     66       {ECO:0000244|PDB:2A2A}.
FT   HELIX        68     80       {ECO:0000244|PDB:2A2A}.
FT   STRAND       89     94       {ECO:0000244|PDB:2A2A}.
FT   STRAND       96    103       {ECO:0000244|PDB:2A2A}.
FT   HELIX       111    116       {ECO:0000244|PDB:2A2A}.
FT   HELIX       123    142       {ECO:0000244|PDB:2A2A}.
FT   STRAND      144    146       {ECO:0000244|PDB:1ZWS}.
FT   HELIX       152    154       {ECO:0000244|PDB:2A2A}.
FT   STRAND      155    158       {ECO:0000244|PDB:2A2A}.
FT   STRAND      162    164       {ECO:0000244|PDB:2A2A}.
FT   STRAND      167    169       {ECO:0000244|PDB:2A2A}.
FT   HELIX       191    193       {ECO:0000244|PDB:2A2A}.
FT   HELIX       196    199       {ECO:0000244|PDB:2A2A}.
FT   HELIX       207    222       {ECO:0000244|PDB:2A2A}.
FT   HELIX       232    240       {ECO:0000244|PDB:2A2A}.
FT   HELIX       248    251       {ECO:0000244|PDB:2A2A}.
FT   HELIX       256    263       {ECO:0000244|PDB:2A2A}.
FT   TURN        270    272       {ECO:0000244|PDB:2A2A}.
FT   HELIX       276    281       {ECO:0000244|PDB:2A2A}.
FT   TURN        283    285       {ECO:0000244|PDB:2A2A}.
FT   HELIX       290    298       {ECO:0000244|PDB:2A2A}.
FT   HELIX       303    312       {ECO:0000244|PDB:2A2A}.
FT   HELIX       314    328       {ECO:0000244|PDB:1ZUZ}.
SQ   SEQUENCE   370 AA;  42898 MW;  035E914BBCD881A2 CRC64;
     MFQASMRSPN MEPFKQQKVE DFYDIGEELG SGQFAIVKKC REKSTGLEYA AKFIKKRQSR
     ASRRGVSREE IEREVSILRQ VLHHNVITLH DVYENRTDVV LILELVSGGE LFDFLAQKES
     LSEEEATSFI KQILDGVNYL HTKKIAHFDL KPENIMLLDK NIPIPHIKLI DFGLAHEIED
     GVEFKNIFGT PEFVAPEIVN YEPLGLEADM WSIGVITYIL LSGASPFLGD TKQETLANIT
     AVSYDFDEEF FSQTSELAKD FIRKLLVKET RKRLTIQEAL RHPWITPVDN QQAMVRRESV
     VNLENFRKQY VRRRWKLSFS IVSLCNHLTR SLMKKVHLRP DEDLRNCESD TEEDIARRKA
     LHPRRRSSTS
//
